<unk>  is a proteasome inhibitor that is FDA approved for the treatment of multiple myeloma.   Common adverse reactions include fatigue, anemia, nausea, thrombocytopenia, dyspnea, diarrhea, and pyrexia.
Carfilzomib
Ixazomib
Bortezomib
Idoxuridine
Busulfan 
Ifosfamide
Floxuridine
Vorinostat